Rosuvastatin PBPK Modeling: Incorporating Liver Concentrations and Effects of Ethnicity, Genetic Polymorphisms, Lactone Formation, DDI and Pregnancy
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.70097 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Ankit Balhara und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: Rosuvastatin Calcium, Liver, Models, Biological, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NICHD NIH HHS.
Abstract (Originalsprache)
Rosuvastatin (RSV), a potent HMG‐CoA reductase inhibitor, is widely used for the management of hyperlipidemia and prevention of cardiovascular disease. Its absorption and disposition are primarily transporter‐mediated, involving intestinal absorption by OATP2B1 and efflux by BCRP; hepatic uptake by OATP1B1, OATP1B3, OATP2B1, and NTCP; and biliary excretion by BCRP and MRP2. Given its minimal metabolism, RSV serves as a model substrate for transporter‐based drug absorption, disposition, and DDI studies. We developed and verified a PBPK model of RSV using a middle‐out approach, incorporating extensive in vitro and in vivo data. The model was verified with > 75 datasets, including plasma and hepatic RSV concentrations from PET imaging studies. The model successfully captured RSV PK profiles in the Caucasian, Chinese, Malay, Japanese, and Korean populations. It also accurately captured the interconversion of RSV and RSV‐lactone, changes in RSV PK due to OATP1B1 and BCRP polymorphisms, and DDI with rifampin or cyclosporine. Sensitivity analyses revealed that reduced hepatic OATP1B1 activity and/or intestinal BCRP efflux are likely determinants of altered RSV PK in the third trimester. Compared to previous models, our model extensively incorporates genetic polymorphisms, ethnic variability, reversible metabolism to the lactone, DDI, and pregnancy, allowing its use in the future to facilitate RSV dose optimization in multiple populations, including pregnant individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, University of Washington, Seattle, WA, USA.
ORCID-Profile: Jashvant D Unadkat
Förderung
- NICHD NIH HHS
Zitieren
APA
Balhara, A., Weber, R. H., & Unadkat, J. D. (2025). Rosuvastatin PBPK Modeling: Incorporating Liver Concentrations and Effects of Ethnicity, Genetic Polymorphisms, Lactone Formation, DDI and Pregnancy. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70097
Vancouver
Balhara A, Weber RH, Unadkat JD. Rosuvastatin PBPK Modeling: Incorporating Liver Concentrations and Effects of Ethnicity, Genetic Polymorphisms, Lactone Formation, DDI and Pregnancy. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70097
BibTeX
@article{Balhara2025,
author = {Balhara, Ankit and Weber, Robert H and Unadkat, Jashvant D},
title = {Rosuvastatin PBPK Modeling: Incorporating Liver Concentrations and Effects of Ethnicity, Genetic Polymorphisms, Lactone Formation, DDI and Pregnancy},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.70097}
}
EUVIMED